Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acorda Therapeutics, Inc. (NASDAQ: ACOR).

Full DD Report for ACOR

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACOR)

Daily Insider Ratings Round Up 12/13/18
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
Source: SeekingAlpha
Date: December, 15 2018 13:24
Centrexion Therapeutics Seeks $75 Million In Proposed IPO
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise $75 million from the sale of its common stock in an IPO. The company is advancing a pipeline of next-generation pain treatment candidates. CNTX has a top-tier CEO, is a mid-stage firm with promising trial results to-date, and h...
Source: SeekingAlpha
Date: November, 05 2018 13:56
Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q3 2018 Results - Earnings Call Transcript
Acorda Therapeutics, Inc. (ACOR) Q3 2018 Earnings Conference Call October 31, 2018 8:30 A.M. ET Executives Felicia Vonella - Executive Director-Investor Relations Ron Cohen - Chief Executive Officer Analysts Carmen Augustine - JPMorgan Kelechi Chikere - Jefferies Phil Nad...
Source: SeekingAlpha
Date: October, 31 2018 14:36
Acorda Therapeutics, Inc. 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: October, 31 2018 09:28
Acorda Therapeutics beats by $0.31, beats on revenue
Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of $0.17 beats by $0.31 ; GAAP EPS of -$0.29 beats by $0.01 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 31 2018 06:01
Acorda Provides Financial and Pipeline Update for Third Quarter 2018
AMPYRA ® (dalfampridine) Q3 2018 net revenue of $138 million; 2018 net revenue guidance increased from $330-$350 million to more than $400 million Cash balance for year-end 2018 revised from more than $300 million to more than $400 million INBRIJA™ (levodopa inhalation...
Source: Business Wire
Date: October, 31 2018 06:00
Notable earnings before Wednesday's open
ACOR , ADP , AEE , AIT , ANTM , APO , APTV , ARCC , AUO , BAX , BCOR , BDC , BG , CAMT , CBZ , CDW , CG , CIM , CLH , CLX , CRTO , CVE , DBD , DIN , EGL , EL , EPD , ETR , GM , GNC , GRMN , HCP , HES , HFC , HSC , IART , ICE , ICPT , IGT , K , LFUS ,...
Source: SeekingAlpha
Date: October, 30 2018 17:30
Centrexion Therapeutics Begins U.S. IPO Effort
Quick Take Centrexion Therapeutics ( CNTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing medication for moderate to severe chronic pain. CNTX is in Phase 3 trials for three programs for its lead ca...
Source: SeekingAlpha
Date: October, 25 2018 16:11
Acorda up 8% premarket on closure of FDA inspections
Acorda Therapeutics (NASDAQ: ACOR ) is up  8%  premarket on light volume on the heels of its disclosure that the FDA's pre-approval inspections of its Chelsea, MA manufacturing facility and the Inbrija inhaler device maker's facility have been completed with no further action req...
Source: SeekingAlpha
Date: October, 18 2018 09:08
Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries - Discovering Underlying Factors of Influence
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunOpta, Inc. (NASDAQ:STKL), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Sap...
Source: GlobeNewswire
Date: October, 17 2018 07:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0827.6027.5527.8027.15233,223
2018-05-1724.4024.1524.6024.05348,700
2017-02-0220.9021.1021.3520.70610,873
2017-02-0120.8520.9521.2520.15532,854
2017-01-3119.4520.5020.7019.30668,386

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1831,94455,26757.7994Short
2018-12-1739,41086,48445.5691Short
2018-12-1437,60954,08969.5317Short
2018-12-1365,045141,98445.8115Short
2018-12-1292,432182,40950.6729Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACOR.


About Acorda Therapeutics, Inc. (NASDAQ: ACOR)

Logo for Acorda Therapeutics, Inc. (NASDAQ: ACOR)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,163,461,422 - 05/14/2018
  • Issue and Outstanding: 46,913,767 - 02/20/2018

 


Recent Filings from (NASDAQ: ACOR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: March, 09 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018

 

 


Daily Technical Chart for (NASDAQ: ACOR)

Daily Technical Chart for (NASDAQ: ACOR)


Stay tuned for daily updates and more on (NASDAQ: ACOR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACOR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACOR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ACOR and does not buy, sell, or trade any shares of ACOR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/